Actinic Keratosis - A Pipeline Analysis Report | Technavio
LONDON--(BUSINESS WIRE)--May 15, 2018-- has announced its latest pipeline analysis report on the . The report comprises an in-depth analysis of the pipeline molecules under investigation within the defined data collection period to treat actinic keratosis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180515005763/en/
Technavio has published a new pipeline analysis report on the global actinic keratosis market, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
Actinic keratosis - market overview
is also known as solar keratosis. It is a patch of scaly, thick skin with a dry and rough texture. It is caused because of prolonged exposure to ultraviolet radiation. Actinic keratosis is termed as a pre-cancerous indication because it has the potential to turn into skin cancer cell. It is the second most common cause of squamous cell carcinoma.
According to a senior analyst at Technavio for , “In people who are exposed to ultraviolet rays for a long time, multiple actinic keratosis lesions may develop on the body parts such as face, scalp, ears, lips, hands, shoulders, and neck. The lesions are easier felt than seen that makes it tough to detect and medicate during the initial stages.”
Actinic keratosis is more common in people who are aged more than 50 years but can affect young adults too. People who live closer to the equator are more affected by actinic keratosis than the ones who live away from the equator. The symptoms of this disease include a wart-like surface or a patch of the epidermis, which can be pink, red, brown, or the same color as the skin.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Actinic keratosis segmentation
This market research report segments the actinic keratosis market based on therapies employed that includes monotherapy, RoA that includes topical, therapeutic modalities (small molecules and phytotherapy), targets for drugs under development (SRC kinase and unknown), and recruitment status (recruiting, completed, and active, not recruiting).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, all the molecules that are being invested are monotherapy.
Topical drugs are applied directly to the body surfaces such as the skin or the mucous membrane. In the current pipeline, all the molecules that are being investigated are being developed for topical administration.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180515005763/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/15/2018 06:54 AM/DISC: 05/15/2018 06:54 AM